Subcutaneous, every-four-week maintenance dosing of a novel protein S antibody is well-tolerated and substantially reduces bleeding rates: results from A phase 1/2 multidose study of VGA039 in patients with von Willebrand disease

Authors
Category Primary study
ConferenceBlood
Year 2025
This article has no abstract
Epistemonikos ID: 1df1426006f5439b0340527431f63c2324c3fe97
First added on: Jun 15, 2026